Drug Delivery Partnering Terms and AgreementsReport Details:Published:November 2012No. of Pages: 1069Price: Single User Li...
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a briefsummary followed by a comprehensi...
•   The leading drug delivery deals by value since 2007•   Most active drug delivery dealmakers since 2007•   The leading ...
2.4. Drug delivery partnering by deal type2.5. Drug delivery partnering by disease type2.6. Partnering by drug delivery te...
4.1. Introduction4.2. How to use bigpharma drug delivery partnering deals4.3. Bigpharma drug delivery partnering company p...
Eli LillyEndo PharmaceuticalsForest LaboratoriesGaldermaGilead SciencesGlaxoSmithKlineGrifolsHospiraJohnson & JohnsonKyowa...
SanofiServierShionogiShireTakedaTevaWarner ChilcottWatsonChapter 5 – Drug delivery partnering contracts directory5.1. Intr...
DevelopmentDistributionEquity purchaseEvaluationGrantJoint ventureLicensingLitigationLoanManufacturingMarketingMaterial tr...
TerminationWarranty5.4. By stage of developmentDiscoveryPreclinicalPhase IPhase IIPhase IIIRegulatoryMarketedFormulation5....
Hospital careImmunologyInfectivesMetabolicMusculoskeletalOncologyOphthalmicsPediatricsRespiratoryChapter 6 – Drug delivery...
Pro-drugTargetedTopicalTransdermalTransmucosalBuccalInhaledNasalOcularRectalSublingualUrogenitalAbout Wildwood VenturesCur...
Appendix 1 – Directory of drug delivery deals by company A-Z 2007-2012Appendix 2 – Directory of drug delivery deals by sta...
Figure 14: Drug delivery deal headline value distribution, US$million – marketed stageFigure 15: Drug delivery deal headli...
Figure 35: Drug delivery deal milestone distribution, US$million – formulation stageFigure 36: Drug delivery deals with ro...
Upcoming SlideShare
Loading in …5
×

Drug Delivery Partnering Terms and Agreements

85 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
85
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Drug Delivery Partnering Terms and Agreements

  1. 1. Drug Delivery Partnering Terms and AgreementsReport Details:Published:November 2012No. of Pages: 1069Price: Single User License – US$2995The Drug Delivery Partnering Terms and Agreements report provides comprehensiveunderstanding and unprecedented access to the drug delivery partnering deals and agreementsentered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter drugdelivery partnering deals. The majority of deals are discovery or development stage whereby thelicensee obtains a right or an option right to license the licensors drug delivery technology. Thesedeals tend to be multicomponent, starting with collaborative R&D, and commercialization ofoutcomes.Understanding the flexibility of a prospective partner’s negotiated deals terms provides criticalinsight into the negotiation process in terms of what you can expect to achieve during thenegotiation of terms. Whilst many smaller companies will be seeking details of the paymentsclauses, the devil is in the detail in terms of how payments are triggered – contract documentsprovide this insight where press releases do not.This report contains over 2,000 links to online copies of actual drug delivery deals and contractdocuments as submitted to the Securities Exchange Commission by companies and theirpartners. Contract documents provide the answers to numerous questions about a prospectivepartner’s flexibility on a wide range of important issues, many of which will have a significantimpact on each party’s ability to derive value from the deal.The initial chapters of this report provide an orientation of drug delivery dealmaking and businessactivities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overviewof the trends in drug delivery dealmaking since 2007, including details of average headline,upfront, milestone and royalty terms.Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed byheadline value, signed by bigpharma, most active bigpharma, and most active of all biopharmacompanies. Where the deal has an agreement contract published at the SEC a link providesonline access to the contract.
  2. 2. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a briefsummary followed by a comprehensive listing of drug delivery deals as well as contract documentsavailable in the public domain. Where available, each deal title links via Weblink to an onlineversion of the actual contract document, providing easy access to each contract document ondemand.Chapter 5 provides a comprehensive and detailed review of drug delivery partnering deals signedand announced since 2007, where a contract document is available in the public domain. Thechapter is organized by company A-Z, stage of development at signing, deal type (collaborativeR&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink toan online version of the deal record and the contract document, providing easy access to eachcontract document on demand.Chapter 6 provides a comprehensive and detailed review of drug delivery partnering dealsorganized by specific drug delivery technology type. Each deal title links via Weblink to an onlineversion of the deal record and where available, the contract document, providing easy access toeach contract document on demand.The report also includes numerous tables and figures that illustrate the trends and activities indrug delivery partnering and dealmaking since 2007.In addition, a comprehensive appendix is provided organized by drug delivery partnering companyA-Z, deal type definitions and drug delivery partnering agreements example. Each deal title linksvia Weblink to an online version of the deal record and where available, the contract document,providing easy access to each contract document on demand.In conclusion, this report provides everything a prospective dealmaker needs to know aboutpartnering in the research, development and commercialization of drug delivery technologies andproducts.Drug Delivery Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to drug delivery trends and structure of deals entered into byleading companies worldwide.This research includes:• Trends in drug delivery dealmaking in the biopharma industry since 2007• Analysis of drug delivery deal structure• Access to headline, upfront, milestone and royalty data• Case studies of real-life drug delivery deals• Access to over 2,000 drug delivery contract documents
  3. 3. • The leading drug delivery deals by value since 2007• Most active drug delivery dealmakers since 2007• The leading drug delivery partnering resourcesIn Drug Delivery Partnering Terms and Agreements, the available contracts are listed by:• Company A-Z• Headline value• Stage of development at signing• Deal component type• Specific therapy targetEach deal title links via Weblink to an online version of the deal record and where available, thecontract document, providing easy access to each contract document on demand.Key Benefits of this report:• In-depth understanding of drug delivery deal trends since 2007• Access to headline, upfront, milestone and royalty data• Analysis of the structure of drug delivery agreements with numerous real life case studies• Comprehensive access to over 2,000 actual drug delivery contracts entered into by the world’s biopharma companies• Detailed access to actual drug delivery contracts enter into by the leading fifty bigpharma companies• Insight into the terms included in a drug delivery agreement, together with real world clause examples• Understand the key deal terms companies have agreed in previous deals• Undertake due diligence to assess suitability of your proposed deal terms for partner companiesGet your copy of this report @http://www.reportsnreports.com/reports/206436-drug-delivery-partnering-terms-and-agreements.htmlMajor points covered in Table of Contents of this report includeExecutive SummaryChapter 1 – IntroductionChapter 2 – Trends in drug delivery dealmaking2.1. Introduction2.2. Drug delivery partnering over the years2.3. Bigpharma drug delivery dealmaking activity
  4. 4. 2.4. Drug delivery partnering by deal type2.5. Drug delivery partnering by disease type2.6. Partnering by drug delivery technology type2.7. Average deal terms for drug delivery partnering2.7.1 Drug delivery headline values2.7.2 Drug delivery upfront payments2.7.3 Drug delivery milestone payments2.7.4 Drug delivery royalty rates2.8. The anatomy of drug delivery partnering2.9. Drug delivery or specialty pharma?2.9.1. Is specialty pharma the only way for drug delivery?2.9.2. Best practice for optimizing drug delivery program development2.9.3. The anatomy of a drug delivery deal2.9.3.a. Case study 1: Alpharma – Durect2.3.3.b. Case study 2: Bayer – MDRNA2.3.3.c. Case study 3: Aradigm – Lung RxChapter 3 – Leading drug delivery deals3.1. Introduction3.2. Top drug delivery deals by valueChapter 4 – Bigpharma drug delivery deals
  5. 5. 4.1. Introduction4.2. How to use bigpharma drug delivery partnering deals4.3. Bigpharma drug delivery partnering company profilesAbbottActavisActelionAllerganAmgenAspen PharmacareAstellasAstraZenecaBaxter InternationalBayerBiogen IdecBoehringer IngelheimBristol-Myers SquibbCelgeneCSLDaiichi SankyoDainippon SumitomoEisai
  6. 6. Eli LillyEndo PharmaceuticalsForest LaboratoriesGaldermaGilead SciencesGlaxoSmithKlineGrifolsHospiraJohnson & JohnsonKyowa Hakko KirinLundbeckMenariniMerck & CoMerck KGaAMitsubishi TanabeNovartisNovo NordiskOtsukaPfizerPurdueRoche
  7. 7. SanofiServierShionogiShireTakedaTevaWarner ChilcottWatsonChapter 5 – Drug delivery partnering contracts directory5.1. Introduction5.2. Company A-Z5.3. By deal typeAsset purchaseAssignmentBigpharma outlicensingCo-developmentCollaborative R&DCo-marketContract serviceCo-promotionCRADA
  8. 8. DevelopmentDistributionEquity purchaseEvaluationGrantJoint ventureLicensingLitigationLoanManufacturingMarketingMaterial transferOptionPromotionResearchRoyalty financingSettlementSpin outSub-licenseSupplyTechnology transfer
  9. 9. TerminationWarranty5.4. By stage of developmentDiscoveryPreclinicalPhase IPhase IIPhase IIIRegulatoryMarketedFormulation5.5. By therapy areaAnaestheticsCardiovascularCentral Nervous SystemDermatologyGastrointestinalGenetic disordersGenitourinaryGynaecologyHematology
  10. 10. Hospital careImmunologyInfectivesMetabolicMusculoskeletalOncologyOphthalmicsPediatricsRespiratoryChapter 6 – Drug delivery dealmaking by technology type6.1. Introduction6.2. Deals by drug delivery typeDrug deliveryBioavailabilityImplantableOral deliveryDelayed releaseRapid releaseParenteralInfusionInjectable
  11. 11. Pro-drugTargetedTopicalTransdermalTransmucosalBuccalInhaledNasalOcularRectalSublingualUrogenitalAbout Wildwood VenturesCurrent PartneringCurrent AgreementsCurrent ReportsRecent titles from CurrentPartneringAppendicesIntroduction
  12. 12. Appendix 1 – Directory of drug delivery deals by company A-Z 2007-2012Appendix 2 – Directory of drug delivery deals by stage of development 2007-2012Appendix 3 – Directory of drug delivery deals by deal type 2007-2012Appendix 4 – Directory of drug delivery deals by therapy area 2007-2012Appendix 5 – Drug delivery partnering resource center Online drug delivery partnering Drugdelivery partnering events Further reading on drug delivery dealmakingTable of FiguresFigure 1: Drug delivery partnering since 2007Figure 2: Bigpharma – top 50 – drug delivery deals 2007 to 2012Figure 3: Bigpharma drug delivery deal frequency – 2007 to 2012Figure 4: Drug delivery partnering by deal type since 2007Figure 5: Drug delivery partnering by disease type since 2007Figure 6: Drug delivery partnering by technology type since 2007Figure 7: Drug delivery deals with a headline valueFigure 8: Drug delivery deal headline value distribution, US$million – discovery stageFigure 9: Drug delivery deal headline value distribution, US$million – preclinical stageFigure 10: Drug delivery deal headline value distribution, US$million – phase I stageFigure 11: Drug delivery deal headline value distribution, US$million – phase II stageFigure 12: Drug delivery deal headline value distribution, US$million – phase III stageFigure 13: Drug delivery deal headline value distribution, US$million – regulatory stage
  13. 13. Figure 14: Drug delivery deal headline value distribution, US$million – marketed stageFigure 15: Drug delivery deal headline value distribution, US$million – formulation stageFigure 16: Summary median headline value by stage of development, 2007-2012Figure 17: Drug delivery deals with upfront payment valuesFigure 18: Drug delivery deal upfront payment distribution, US$million – discovery stageFigure 19: Drug delivery deal upfront payment distribution, US$million – preclinical stageFigure 20: Drug delivery deal upfront payment distribution, US$million – phase I stageFigure 21: Drug delivery deal upfront payment distribution, US$million – phase II stageFigure 22: Drug delivery deal upfront payment distribution, US$million – phase III stageFigure 23: Drug delivery deal upfront payment distribution, US$million – regulatory stageFigure 24: Drug delivery deal upfront payment distribution, US$million – marketed stageFigure 25: Drug delivery deal upfront payment distribution, US$million – formulation stageFigure 26: Summary median upfront payments by stage of development, 2007-2012Figure 27: Drug delivery deals with milestone paymentsFigure 28: Drug delivery deal milestone distribution, US$million – discovery stageFigure 29: Drug delivery deal milestone distribution, US$million – preclinical stageFigure 30: Drug delivery deal milestone distribution, US$million – phase I stageFigure 31: Drug delivery deal milestone distribution, US$million – phase II stageFigure 32: Drug delivery deal milestone distribution, US$million – phase III stageFigure 33: Drug delivery deal milestone distribution, US$million – regulatory stageFigure 34: Drug delivery deal milestone distribution, US$million – marketed stage
  14. 14. Figure 35: Drug delivery deal milestone distribution, US$million – formulation stageFigure 36: Drug delivery deals with royalty rates, %Figure 37: Drug delivery deal royalty rate distribution, US$million – discovery stageFigure 38: Drug delivery deal royalty rate distribution, US$million – preclinical stageFigure 39: Drug delivery deal royalty rate distribution, US$million – phase I stageFigure 40: Drug delivery deal royalty rate distribution, US$million – phase II stageFigure 41: Drug delivery deal royalty rate distribution, US$million – phase III stageFigure 42: Drug delivery deal royalty rate distribution, US$million – regulatory stageFigure 43: Drug delivery deal royalty rate distribution, US$million – marketed stageFigure 44: Drug delivery deal royalty rate distribution, US$million – formulation stageFigure 45: Summary median royalty rate by stage of development, 2007-2012Figure 46: Components of the typical drug delivery deal structureFigure 47: Best practice for drug delivery program developmentFigure 48: Top drug delivery deals by value since 2007Contact: sales@reportsandreports.com for more information.

×